← All trials
NCT04695197
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 8, 2021
- Primary completion
- Nov 1, 2022
- Completion date
- Jul 31, 2023
- First posted
- Jan 5, 2021
- Last posted
- Feb 24, 2021
- Enrollment
- 142
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LiverpoolLead sponsor
- Government of KenyaCollaborator
- University of LondonCollaborator
- Centers for Disease Control and Prevention (CDC)Collaborator
- Kenya Medical Research InstituteOverall official - principal investigator
- Kenya Medical Research InstituteCollaborator
- Bill and Melinda Gates FoundationCollaborator
- Groupe de Recherche Action en Santé (GRAS), Burkina FasoCollaborator
- Groupe de Recherche Action en Santé (GRAS), Burkina FasoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.